Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 20:36:10704.
doi: 10.3389/ti.2023.10704. eCollection 2023.

Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination

Steven Ivulich  1   2 , Eldho Paul  3 , Carl Kirkpatrick  2 , Michael Dooley  1   2 , Greg Snell  1
Affiliations

Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination

Steven Ivulich et al. Transpl Int. .

Abstract

Everolimus (EVE) provides an alternative to maintenance immunosuppression when conventional immunosuppression cannot be tolerated. EVE can be utilized with a calcineurin inhibitor (CNI) minimization or elimination strategy. To date, clinical studies investigating EVE after lung transplant (LTx) have primarily focused on the minimization strategy to preserve renal function. The primary aim was to determine the preferred method of EVE utilization for lung transplant recipients (LTR). To undertake this aim, we compared the safety and efficacy outcomes of EVE as part of minimization and elimination immunosuppressant regimens. Single center retrospective study of 217 LTR initiated on EVE (120 CNI minimization and 97 CNI elimination). Survival outcomes were calculated from the date of EVE commencement. On multivariate analysis, LTR who received EVE as part of the CNI elimination strategy had poorer survival outcomes compared to the CNI minimization strategy [HR 1.61, 95% CI: 1.11-2.32, p=0.010]. Utilization of EVE for renal preservation was associated with improved survival compared to other indications [HR 0.64, 95% CI: 0.42-0.97, p=0.032]. EVE can be successfully utilized for maintenance immunosuppression post LTx, particularly for renal preservation. However, immunosuppressive regimens containing low dose CNI had superior survival outcomes, highlighting the importance of retaining a CNI wherever possible.

Keywords: calcineurin inhibitor; everolimus; lung transplant recipients; lung transplant survival; lung transplantation; mammalian-target-of-rapamycin inhibitor; nephrotoxicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Kaplan-Meier curve showing overall survival by elimination versus minimization. p-value is calculated from a log rank test comparing the entire survival experience between the two groups (minimization versus elimination).
FIGURE 2
FIGURE 2
Kaplan-Meier curve showing overall survival by renal preservation versus other indications.
FIGURE 3
FIGURE 3
Creatinine and estimated glomerular filtration rate (eGFR) changes from time to switch to 3 months.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ivulich S, Westall G, Dooley M, Snell G. The Evolution of Lung Transplant Immunosuppression. Drugs (2018) 78(10):965–82. 10.1007/s40265-018-0930-6 - DOI - PubMed
    1. Penninga L, Penninga EI, Moller CH, Iversen M, Steinbruchel DA, Gluud C. Tacrolimus versus Cyclosporin as Primary Immunosuppression for Lung Transplant Recipients. Cochrane Database Syst Rev (2013) 5:CD008817. 10.1002/14651858.CD008817.pub2 - DOI - PubMed
    1. Grass F, Schafer M, Cristaudi A, Berutto C, Aubert JD, Gonzalez M, et al. Incidence and Risk Factors of Abdominal Complications after Lung Transplantation. World J Surg (2015) 39(9):2274–81. 10.1007/s00268-015-3098-1 - DOI - PubMed
    1. Bravo C, Gispert P, Borro JM, de la Torre M, Cifrian Martinez JM, Fernandez Rozas S, et al. Prevalence and Management of Gastrointestinal Complications in Lung Transplant Patients: MITOS Study Group. Transpl Proc (2007) 39(7):2409–12. 10.1016/j.transproceed.2007.07.054 - DOI - PubMed
    1. Hackman KL, Bailey MJ, Snell GI, Bach LA. Diabetes Is a Major Risk Factor for Mortality after Lung Transplantation. Am J Transpl (2014) 14(2):438–45. 10.1111/ajt.12561 - DOI - PubMed

LinkOut - more resources